葡萄籽提取物与微粒化纯化黄酮组分治疗慢性静脉疾病患者的比较:一项随机非劣效性试验
这项双盲前瞻性随机试验纳入13家医院303例慢性静脉疾病患者,随机接受葡萄籽提取物(n=154)或微粒化纯化黄酮组分(n=149)。8周时两组CIVIQ-20评分均较基线显著降低,组间变化无显著差异,95%CI下限在预设非劣效界值6.9内,葡萄籽提取物不劣于微粒化纯化黄酮组分。
要点
- 葡萄籽提取物组与微粒化纯化黄酮组分组的8周CIVIQ-20评分变化无显著组间差异。
- 葡萄籽提取物在缓解静脉症状和改善生活质量方面不劣于微粒化纯化黄酮组分。
- 两组Aberdeen静脉曲张问卷、视觉模拟量表及静脉临床严重程度评分在4周和8周均较基线显著下降。
核心结论
- 葡萄籽提取物在缓解静脉症状和改善慢性静脉疾病患者生活质量方面不劣于微粒化纯化黄酮组分。
研究设计与样本
- 双盲前瞻性随机试验,纳入13家医院经双腔超声诊断为静脉功能不全且CEAP临床分级为1、2或3级的患者。
- 共303例患者随机接受葡萄籽提取物(n=154)或微粒化纯化黄酮组分(n=149)。
主要发现
- 8周时两组CIVIQ-20评分均较基线显著降低,组间变化无显著差异(-8.31 ± 14.63 vs. -10.35 ± 14.38,P = 0.29,95%CI -1.65至5.72)。
- 95%CI下限在预设非劣效界值6.9内。
- 两组Aberdeen静脉曲张问卷、视觉模拟量表及静脉临床严重程度评分在随机化后4周和8周均较基线显著下降,组间各评分降低幅度无显著差异。
- 接受葡萄籽提取物治疗的患者8周时小腿周径较基线显著减小。
关键数值与推荐
- 主要结局为8周时CIVIQ-20评分较基线的变化。
- 预设非劣效界值为6.9。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venoactive drugs (VADs) based on Vitis vinifera extract are widely used in Korea. However, studies on the clinical effects and head-to-head comparisons with other groups of VADs are limited. This trial aimed to evaluate whether Vitis vinifera seed extract was noninferior to the micronized purified flavonoid fraction (MPFF) in relieving venous symptoms and improving quality of life in patients with chronic venous disease. METHODS: In this double-blind prospective randomized trial, patients from 13 hospitals, who were diagnosed with venous incompetence by duplex ultrasound and classified as clinical class 1, 2, or 3 in the Clinical, Etiological, Anatomical, and Pathophysiological classifications were enrolled. The primary outcome was the change in the Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20) score at 8 weeks from baseline. Secondary outcomes included changes in the Aberdeen Varicose Vein Questionnaire, visual analog scale, and Venous Clinical Severity Score at 4 and 8 weeks from baseline. Moreover, the change in leg circumferences was measured at 8 weeks and compared to baseline. RESULTS: In total, 303 patients were enrolled and randomly assigned to receive either Vitis vinifera seed extract (n = 154) or MPFF (n = 149). The CIVIQ-20 scores at 8 weeks were significantly reduced compared to those at baseline in both groups. No significant intergroup difference in the change of CIVIQ-20 at 8 weeks from baseline was observed (-8.31 ± 14.63 vs. -10.35 ± 14.38, P = 0.29, 95% confidence interval -1.65 to 5.72). The lower limit of the 95% confidence interval was within the predefined noninferiority margin of 6.9. Furthermore, the Aberdeen Varicose Vein Questionnaire, visual analog scale, and Venous Clinical Severity Score scores significantly decreased at 4 and 8 weeks after randomization compared with baseline in both groups. No significant differences were observed in the reduction of each score between groups. The calf circumference measured at 8 weeks was significantly reduced compared to that at baseline in patients receiving Vitis vinifera seed extract. CONCLUSIONS: Vitis vinifera seed extract was noninferior to MPFF in relieving venous symptoms and improving the quality of life in patients with chronic venous disease.
引用
- Kim SM, Joh JH, Jung IM, et al. Vitis Vinifera Seed Extract Versus Micronized Purified Flavonoid Fraction for Patients with Chronic Venous Disease: A Randomized Noninferiority Trial. Ann Vasc Surg. 2024. PMID: 39009117. doi:10.1016/j.avsg.2024.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。